These reports were followed by a well-done tumoral PD study in colorectal cancer patients who received selumetinib and the AKT inhibitor MK-2206 and who underwent serial biopsies for quantitative measurements of p-ERK and p-AKT levels pre- and on-treatment [22]. This evidence concerns the gene AKT1 and colorectal cancer.